Regulation of cisplatin resistance in bladder cancer by epigenetic mechanisms

Drug Resistance Updates(2023)

引用 12|浏览18
暂无评分
摘要
Bladder cancer is one of the most common malignancies in the world. Cisplatin is one of the most potent and widely used anticancer drugs and has been employed in several malignancies. Cisplatin-based combination chemotherapies have become important adjuvant therapies for bladder cancer patients. Cisplatin-based treatment often results in the development of chemoresistance, leading to therapeutic failure and limiting its application and effectiveness in bladder cancer. To develop improved and more effective cancer therapy, research has been conducted to elucidate the underlying mechanism of cisplatin resistance. Epigenetic modifications have been demonstrated involved in drug resistance to chemotherapy, and epigenetic biomarkers, such as urine tumor DNA methylation assay, have been applied in patients screening or monitoring. Here, we provide a systematic description of epigenetic mechanisms, including DNA methylation, noncoding RNA regulation, m6A modification and posttranslational modifications, related to cisplatin resistance in bladder cancer.
更多
查看译文
关键词
NMIBC,MIBC,TLX3,HOXA9,GULP1,KEAP1,NRF2,UCB,ASS1,SAT1,ADI-PEG 20,DNMTs,CSCs,DAC,SOCS3,RASSF1A,CTGF,CYR61,MiRNA,HAX-1,EHHADH,CpG,IGFBP3,ICAM1,TNFSF10,HIF-1α,SIRT4,hTERT,PDCD4,AKT,mTOR,VEGFC,ERK5,PPP2R2A,NRAS,PI3K,JAK,STAT,CDK6,GOLPH3,BMI1,ABCB1,P-GP,GSH,SLC7A11,EZH2,PLCε,PNPT1,BMF,CEBPD,PARP,TCC,ROCK,LncRNA,MEG3,MMP2,MMP9,PVT1,DOX,LMAN1,HIF1A-AS2,HMGA1,NEAT1,MYC,OCT4,UCA1,CUDR,CREB,ceRNAs,DLEU1,HS3ST3B1,TUG1,CCND2,MALAT1,EMT,CircRNAs,ncRNAs,APAF1,AR,ARE,KRAS,MSH2,CDC25B,M6a,MDSCs,METTL3,WTAP,MDSC,TNFAIP3,ALKBH5,CK2α,G-CSF,PTMs,SUMO,AC,ENT,ER-β,FGFR3,FOXO1,GRIM19,CIP2A,HATs,HDACs,HMGN5,KDM7A,Me,SPHK1,USP14,USP21,Ub,WDR5,MAPK,JNK,CDK2,MDR1,ACSS2,FASN,OGT,VPA
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要